By QPCR, we observed elevated expression levels of both CCR7 and CCL21 in a cohort of 14 WHO grade IV GBM compared to 11 LGG patients (WHO grade I, II, and III gliomas) (Fig. 1b, Table 1). The gene discussed is CCL21; the disease is central nervous system cancer.